Cargando…
Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study
PURPOSE: this study was conducted to assess the impact of AIs on body mass index and high sensitivity as prognostic predictors to be incorporated into point of care technology (POCT) testing in postmenopausal breast cancer women after a 24 month follow up in Africa. An observational cohort study was...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012500/ https://www.ncbi.nlm.nih.gov/pubmed/36915158 http://dx.doi.org/10.1186/s13104-023-06301-6 |
_version_ | 1784906616894652416 |
---|---|
author | Milambo, Jean Paul Muambangu Nyasulu, Peter S Akudugu, John M Ndirangu, James |
author_facet | Milambo, Jean Paul Muambangu Nyasulu, Peter S Akudugu, John M Ndirangu, James |
author_sort | Milambo, Jean Paul Muambangu |
collection | PubMed |
description | PURPOSE: this study was conducted to assess the impact of AIs on body mass index and high sensitivity as prognostic predictors to be incorporated into point of care technology (POCT) testing in postmenopausal breast cancer women after a 24 month follow up in Africa. An observational cohort study was conducted; including 126 female BC patients with stages ranging from 0-III initially subjected to AIs and subsequently followed up for 24 months. Multiple imputation model was conducted to predict missing data. RESULTS: Random effects model was used to monitor the changes over the time. The study revealed stronger statistically association between BMI and homocysteine (p = 0.021, 95%CI: 0.0083 to 0.1029). Weight and total body fat were strongly associated after 24 months follow up. Hs-CRP was associated with BMI (p = 0.0001), and hs-CRP was associated with other biomedical markers such as calcium (p = 0.021, 95% CI: 0.01 to 0.10), phosphate (p = 0.039, 95%CI: 0.01 to 0.10), and ferritin (p = 0.002, 95%CI: 0.02 to 0.08) and calcium. The patients subjected to AIs are likely to develop cardiovascular adverse events. POCT of care strategy which include clinical, biomedical and genetic predictor’s measurement is required to improve BC survivorship. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-023-06301-6. |
format | Online Article Text |
id | pubmed-10012500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100125002023-03-15 Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study Milambo, Jean Paul Muambangu Nyasulu, Peter S Akudugu, John M Ndirangu, James BMC Res Notes Research Note PURPOSE: this study was conducted to assess the impact of AIs on body mass index and high sensitivity as prognostic predictors to be incorporated into point of care technology (POCT) testing in postmenopausal breast cancer women after a 24 month follow up in Africa. An observational cohort study was conducted; including 126 female BC patients with stages ranging from 0-III initially subjected to AIs and subsequently followed up for 24 months. Multiple imputation model was conducted to predict missing data. RESULTS: Random effects model was used to monitor the changes over the time. The study revealed stronger statistically association between BMI and homocysteine (p = 0.021, 95%CI: 0.0083 to 0.1029). Weight and total body fat were strongly associated after 24 months follow up. Hs-CRP was associated with BMI (p = 0.0001), and hs-CRP was associated with other biomedical markers such as calcium (p = 0.021, 95% CI: 0.01 to 0.10), phosphate (p = 0.039, 95%CI: 0.01 to 0.10), and ferritin (p = 0.002, 95%CI: 0.02 to 0.08) and calcium. The patients subjected to AIs are likely to develop cardiovascular adverse events. POCT of care strategy which include clinical, biomedical and genetic predictor’s measurement is required to improve BC survivorship. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-023-06301-6. BioMed Central 2023-03-13 /pmc/articles/PMC10012500/ /pubmed/36915158 http://dx.doi.org/10.1186/s13104-023-06301-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Note Milambo, Jean Paul Muambangu Nyasulu, Peter S Akudugu, John M Ndirangu, James Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study |
title | Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study |
title_full | Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study |
title_fullStr | Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study |
title_full_unstemmed | Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study |
title_short | Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study |
title_sort | long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in africa: observational cohort study |
topic | Research Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012500/ https://www.ncbi.nlm.nih.gov/pubmed/36915158 http://dx.doi.org/10.1186/s13104-023-06301-6 |
work_keys_str_mv | AT milambojeanpaulmuambangu longtermeffectsofaromataseinhibitorsonbodymassindexamongpostmenopausalbreastcancersurvivorsinafricaobservationalcohortstudy AT nyasulupeters longtermeffectsofaromataseinhibitorsonbodymassindexamongpostmenopausalbreastcancersurvivorsinafricaobservationalcohortstudy AT akudugujohnm longtermeffectsofaromataseinhibitorsonbodymassindexamongpostmenopausalbreastcancersurvivorsinafricaobservationalcohortstudy AT ndirangujames longtermeffectsofaromataseinhibitorsonbodymassindexamongpostmenopausalbreastcancersurvivorsinafricaobservationalcohortstudy |